• Conditions & Treatments

  • Learn from the Experts

  • Support Your Practice

  • Conferences & Highlights

  • Community Resources

  • Our Expert Network

CME & EducationAbout Us
Loading...
CME & EducationAbout Us
Loading profile...
  • Conditions & Treatments

  • Learn from the Experts

  • Support Your Practice

  • Conferences & Highlights
  • Community Resources

  • Our Expert Network
  1. Home
  2. Videos
  3. Discourses In Dermatology
  4. Exploring Emerging Dermatology Devices And Treatments In 2025

Exploring Emerging Dermatology Devices and Treatments in 2025

Featuring:
SLStephen Lewellis, MD, PhD, FAADFaculty
Updated:Jan 7, 2025
AcneAcnePractice Management

About this video

In this episode of Topical Conversations, Dr Stephen Lewellis provides an insightful overview of the evolving landscape of dermatology devices and treatments to watch in 2025. Sharing his personal insights and experiences, Dr Lewellis highlights how these innovations can enhance patient outcomes and help dermatologists distinguish their practice by offering unique and forward-thinking options that patients may not encounter elsewhere. 

AviClear for acne 

Dr Lewellis begins by discussing AviClear, a 1726-nanometer laser device FDA cleared for treating acne of all severities. He highlights its best use cases, including moderate to severe inflammatory acne and patients who cannot or do not wish to take isotretinoin. 

  • Treatment overview: Three treatments over 2 months with optimal results typically appearing 6 to 12 months post-treatment 
  • Patient counseling: Emphasize patience and realistic expectations for long-term improvement 
  • Cost consideration: Though not covered by insurance, it may be more affordable than isotretinoin in some cases 

Dr Lewellis advises dermatologists to consider AviClear as part of their practice or refer patients to trusted colleagues who offer this treatment to provide comprehensive care. 

excel V+ Plus for versatile needs 

The excel V+ device features the Laser Genesis treatment mode, which uses 532- or 1064-nanometer lasers to induce dermal heating. 

  • Treatment benefits: Improved complexion, reduced pore size, and some acne improvement with minimal downtime 
  • Expectations: While optimal results require 6 to 8 treatments, even 1 to 2 sessions can provide improvement 
  • Applications: Beyond aesthetics, excel V+ can treat rosacea, inflammatory acne, and more, making it a versatile addition to a dermatology practice 

Swift for refractory warts 

Swift uses focused microwave energy to treat warts, especially plantar warts, by inducing a heat response that stimulates an immune reaction against the virus. 

  • Advantages: Less painful than cryosurgery with no post-treatment wound formation 
  • Key use case: Can be effective for refractory warts across the body

 Dr Lewellis notes that Swift is a niche offering that can help dermatologists stand out in their communities. 

YCANTH for molluscum contagiosum 

While not a device, YCANTH is a standardized form of cantharidin for molluscum contagiosum. 

  • Treatment highlights: Reliable, controlled results with treatments every 3 weeks as needed 
  • Controversy: While compounded cantharidin remains an option, consistency and robust data make YCANTH worth considering for patients 

Setting your practice apart 

Dr Lewellis concludes by advising that incorporating innovative devices and treatments such as AviClear, excel V+, and Swift, along with in-office options like YCANTH, represents an opportunity for dermatologists to differentiate their practices in 2025. These technologies offer cutting-edge solutions that can improve patient outcomes and expand treatment options. Exploring and integrating these advancements can help establish a practice as a leader in forward-thinking dermatologic care, enhancing both patient satisfaction and professional reputation within the community.

1
Integrating 31-GEP Testing into SLNB Decision-Making in Cutaneous Melanoma
5:04

Integrating 31-GEP Testing into SLNB Decision-Making in Cutaneous Melanoma

2
What Changes When We Treat Psoriasis as Systemic Disease?
7:01

What Changes When We Treat Psoriasis as Systemic Disease?

3
Who to Look for and When to Act
2:31

Who to Look for and When to Act

4
How Oral TYK2 Inhibition Is Showing Up in Real Decisions
10:38

How Oral TYK2 Inhibition Is Showing Up in Real Decisions

5
Injecting on Bone: A Practical Approach to Filler Safety
0:44

Injecting on Bone: A Practical Approach to Filler Safety

6
Cosibelimab in Advanced Cutaneous Squamous Cell Carcinoma: ≥2-Year Follow-Up from the Pivotal Study
8:12

Cosibelimab in Advanced Cutaneous Squamous Cell Carcinoma: ≥2-Year Follow-Up from the Pivotal Study

7
Earlier Treatment, Different Outcomes: Secukinumab and the HS Disease Course
2:51

Earlier Treatment, Different Outcomes: Secukinumab and the HS Disease Course

8
Fast Relief, Sustained Control: What Remibrutinib Shows in CSU
2:42

Fast Relief, Sustained Control: What Remibrutinib Shows in CSU

9
Bullous Pemphigoid: The Evolving Treatment Landscape
8:22

Bullous Pemphigoid: The Evolving Treatment Landscape

10
Confirming BP Diagnosis and Choosing Treatment
7:42

Confirming BP Diagnosis and Choosing Treatment

11
How Dermatologists Use Hedgehog Inhibitors for Locally Advanced BCC
4:08

How Dermatologists Use Hedgehog Inhibitors for Locally Advanced BCC

12
What Four Years Can Tell Us About Treating Moderate to Severe HS
3:29

What Four Years Can Tell Us About Treating Moderate to Severe HS

13
Early Response, Sustained Control: 52-Week Outcomes With Remibrutinib
3:18

Early Response, Sustained Control: 52-Week Outcomes With Remibrutinib

14
A Review of Dermoscopy Techniques With Michelle Tarbox, MD
1:28

A Review of Dermoscopy Techniques With Michelle Tarbox, MD

15
Leading With Intention in Aesthetic Assessment
2:57

Leading With Intention in Aesthetic Assessment

16
Recognizing Bullous Pemphigoid Earlier in Clinical Practice
1:52

Recognizing Bullous Pemphigoid Earlier in Clinical Practice

17
Tildrakizumab in Psoriasis: Adherence, Persistence, and the Role of In-Office Administration
10:34

Tildrakizumab in Psoriasis: Adherence, Persistence, and the Role of In-Office Administration

18
Advancing Bullous Pemphigoid Care: Clinical Insights From Dr. Del Rosso
23:00

Advancing Bullous Pemphigoid Care: Clinical Insights From Dr. Del Rosso

19
Strengthening Confidence in Hedgehog Inhibitors for Locally Advanced Basal Cell Carcinoma
8:33

Strengthening Confidence in Hedgehog Inhibitors for Locally Advanced Basal Cell Carcinoma

20
Advancing Melanoma Prognostics: Clinical Evidence Supporting the 31-GEP Test
6:53

Advancing Melanoma Prognostics: Clinical Evidence Supporting the 31-GEP Test

21
Topical Truths: Managing AD in the Real World
21:54

Topical Truths: Managing AD in the Real World

22
The Oral Conversation: How We Talk to Patients About Systemic Therapy Today
30:51

The Oral Conversation: How We Talk to Patients About Systemic Therapy Today

23
Part 4: How Dermatologists Approach SI/B Warnings in Daily Practice
10:00

Part 4: How Dermatologists Approach SI/B Warnings in Daily Practice

24
Part 1: Psoriasis and Mental Health: Understanding Depression and Suicidality Risk
10:04

Part 1: Psoriasis and Mental Health: Understanding Depression and Suicidality Risk

25
Part 2: Psoriasis and Mental Health: The Inflammatory and Biochemical Pathways
9:36

Part 2: Psoriasis and Mental Health: The Inflammatory and Biochemical Pathways

26
Part 3: Psoriasis and Mental Health: How to Navigate SI/B Warnings With Patients
9:51

Part 3: Psoriasis and Mental Health: How to Navigate SI/B Warnings With Patients

27
Fall Clinical Continuity Experience - Vtama - Lecture Recap Video
0:35

Fall Clinical Continuity Experience - Vtama - Lecture Recap Video

28
Four Years of Data: Durability and Distinction with TYK2 Inhibition
3:09

Four Years of Data: Durability and Distinction with TYK2 Inhibition

29
What an Oral Option Means for Psoriasis Care
2:34

What an Oral Option Means for Psoriasis Care

30
LAUNCH ALERT: FDA Approves Anzupgo (Delgocitinib) Cream for Moderate-to-Severe Chronic Hand Eczema in Adults
8:39

LAUNCH ALERT: FDA Approves Anzupgo (Delgocitinib) Cream for Moderate-to-Severe Chronic Hand Eczema in Adults

31
Bimzelx in Focus: Versatile Care for Enhanced Dermatologic Outcomes
7:58

Bimzelx in Focus: Versatile Care for Enhanced Dermatologic Outcomes

32
Discover VTAMA: A Next-Generation Treatment for Plaque Psoriasis
4:59

Discover VTAMA: A Next-Generation Treatment for Plaque Psoriasis

33
VTAMA: A New Standard in Psoriasis Management
4:59

VTAMA: A New Standard in Psoriasis Management

34
Exploring the MyPath Melanoma Test for Guiding Management and Care Decisions in Patients with Ambiguous Lesions
18:17

Exploring the MyPath Melanoma Test for Guiding Management and Care Decisions in Patients with Ambiguous Lesions

35
Bimekizumab for Plaque Psoriasis: Its Impact in Clinical Practice
16:27

Bimekizumab for Plaque Psoriasis: Its Impact in Clinical Practice

36
Bimekizumab for Plaque Psoriasis: Insights into Efficacy, Safety, and Dosing
6:45

Bimekizumab for Plaque Psoriasis: Insights into Efficacy, Safety, and Dosing

37
Psoriasis mechanism of disease: Pathogenesis
8:27

Psoriasis mechanism of disease: Pathogenesis

38
Psoriasis mechanism of disease: Genetic, environmental, and lifestyle factors
12:45

Psoriasis mechanism of disease: Genetic, environmental, and lifestyle factors

Dermsquared

The leading solutions platform for dermatology professionals to elevate patient care.

Helpful Links

Terms of Service

Editorial & Medical Review Policy

Privacy Policy

Cookie Policy

Contact Us

Support

Subscribe now

Enter your email to get the latest updates.

© 2026 dermsquared | All Rights Reserved

Continuing Education

0.75 Credits

DermInsider - VGR Session 11

Welcome to DermInsider - A Virtual Grand Rounds SeriesNew name, the same great CME!DermInsider consists of regularly scheduled CME sessions on a variety of dermatological diseases, delivered by the top experts in dermatology. Please join us for this week's session:Wednesday, October 15, 20258 PM ET / 5 PM PTThe Science of Botulinum Toxin Type A – Mark Nestor, MD, PhDClinical Updates in Acne and Rosacea – Linda Stein Gold, MD